Results 1 to 10 of about 174,072,709 (188)

Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes [PDF]

PLoS ONE, 2023
Acute kidney injury is considered an independent prognostic factor for mortality in patients with liver cirrhosis. Non-treated acute kidney injury can progress to hepatorenal syndrome with a poor prognosis. As suppression of tumorigenicity 2 (ST2) is a member of the interleukin-1 receptor family that aggravates inflammation and fibrotic changes in ...
Jong Joo Moon, Suk Kyun Hong, Yong Chul Kim, Su young Hong, YoungRok choi, Nam-Joon Yi, Kwang-Woong Lee, Seung Seok Han, Hajeong Lee, Dong Ki Kim, Yon Su Kim, Seung Hee Yang, Kyung-Suk Suh   +12 more
doaj   +5 more sources

Soluble suppression of tumorigenicity 2 associated with atrial fibrillation detected after stroke: A retrospective study [PDF]

Heliyon, 2023
Background: The soluble suppression of tumorigenicity 2 (sST2) is closely associated with stroke and atrial fibrillation (AF). However, no studies on sST2 and AF detected after stroke (AFDAS) have been reported.
Wenquan Hou, Yong Li, Jing Wang, Menghua Xu, Siwen Wu, Wen Li, Suhua Qi   +6 more
doaj   +6 more sources

Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis [PDF]

BMC Gastroenterology
Background & aims With the increase in patients at risk of advanced liver disease due to the obesity epidemic, there will be a need for simple screening tools for advanced liver fibrosis.
Florian F. Hildenbrand, Barbara Illi, Stefanie von Felten, Jacqueline Bachofner, Joanna Gawinecka, Arnold von Eckardstein, Beat Müllhaupt, Joachim C. Mertens, Sena Blümel   +8 more
doaj   +7 more sources

The soluble suppression of tumorigenicity 2 as a biomarker of early cardiac remodeling in bradycardia patients receiving permanent pacemaker therapy [PDF]

Future Science OA, 2023
Aim: This study aims to evaluate: the difference of soluble suppression of tumorigenicity 2 (sST2) level, a biomarker for cardiac remodeling and echocardiography parameters value prior to and 1 month after implantation; and the association between ...
Mohammad Iqbal, Iwan Cahyo Santosa Putra, Rizki Bunawan, Hanna Goenawan, Mohammad Rizki Akbar, Arief Sjamsulaksan Kartasasmita, Young Hoon Kim   +6 more
doaj   +5 more sources

Predictive value of soluble suppression of tumorigenicity 2 in atrial fibrillation: a systematic review and meta-analysis [PDF]

Frontiers in Cardiovascular Medicine, 2023
PurposeAtrial fibrosis is the main pathological basis for the pathogenesis and progression of atrial fibrillation (AF). Soluble suppression of tumorigenicity 2 (sST2) is involved in fibrosis.
Pengfei Chen, Pengfei Chen, Jie Zhang, Jianpeng Du, Jianpeng Du, Dazhuo Shi, Dazhuo Shi, He Zhang, He Zhang   +8 more
doaj   +4 more sources

Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure [PDF]

Critical Care Explorations, 2021
OBJECTIVES:. We hypothesize that elevated soluble suppression of tumorigenicity-2 concentrations, a marker of pulmonary epithelial injury, reflect ongoing lung injury in acute hypoxemic respiratory failure due to coronavirus disease 2019 and associate ...
Jehan W. Alladina, MD, Francesca L. Giacona, BS, Emma B. White, BS, Kelsey L. Brait, BS, Elizabeth A. Abe, BS, Sam A. Michelhaugh, BS, Kathryn A. Hibbert, MD, James L. Januzzi, MD, B. Taylor Thompson, MD, Josalyn L. Cho, MD, Benjamin D. Medoff, MD   +10 more
doaj   +4 more sources

Soluble suppression of tumorigenicity 2 associated with major adverse cardiac events in children with myocarditis [PDF]

Frontiers in Cardiovascular Medicine
ObjectiveSoluble suppression of tumorigenicity 2 (sST2) is associated with the prognosis of some cardiac diseases, but studies on sST2 and the prognosis of patients with myocarditis are rare. This study investigated the relationship between major adverse
Tongtong Shi, Jing Ge, Shan Li, Yali Zhang   +3 more
doaj   +4 more sources

Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect [PDF]

Pulmonary Circulation, 2020
Uncorrected atrial septal defect undergoes right ventricle chronic volume overload which may lead to pulmonary hypertension and Eisenmenger Syndrome. The soluble suppression of tumorigenicity-2 is a left ventricle strain biomarker; however, its role in ...
Reza S. Pratama, Anggoro B. Hartopo, Dyah W. Anggrahini, Vera C. Dewanto, Lucia K. Dinarti   +4 more
doaj   +3 more sources

Soluble suppression of tumorigenicity 2 as outcome predictor after cardiopulmonary resuscitation: an observational prospective study [PDF]

Scientific Reports, 2021
Prognostication after cardiopulmonary resuscitation (CPR) is complex. Novel biomarkers like soluble suppression of tumorigenicity 2 (sST2) may provide an objective approach.
Richard Rezar, Vera Paar, Clemens Seelmaier, Ingrid Pretsch, Philipp Schwaiger, Kristen Kopp, Reinhard Kaufmann, Thomas K. Felder, Erika Prinz, Geza Gemes, Rudin Pistulli, Uta C. Hoppe, Bernhard Wernly, Michael Lichtenauer   +13 more
doaj   +5 more sources

Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction [PDF]

BMC Cardiovascular Disorders
Background Microvascular obstruction (MVO) develops in approximately 50% of patients with ST-segment elevation myocardial infarction (STEMI) after undergoing percutaneous coronary intervention (PCI).
Xinjia Du, Jiahua Liu, Jingfang Zhou, Yanfei Ren, Nauman Gul, Lei Chen, Yuan Lu   +6 more
doaj   +4 more sources